Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease

被引:0
|
作者
Clara Antoury [1 ]
Rocio Lopez [2 ]
Nizar Zein [3 ]
James K Stoller [4 ]
Naim Alkhouri [3 ]
机构
[1] Department of Internal Medicine,Cleveland Clinic Foundation
[2] Department of Quantitative Health Sciences,Cleveland Clinic Foundation
[3] Department of Gastroenterology and Hepatology and Digestive Disease Institute,Cleveland Clinic Foundation
[4] Departments of Pulmonary and Critical Care,Respiratory Institute and Education Institute,Cleveland Clinic Foundation
关键词
Hepatocellular carcinoma; Liver cirrhosis; End-stage liver disease; Hepatitis C virus; Alpha-1 antitrypsin deficiency;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
AIM:To evaluate the association between alpha-1 antitrypsin deficiency(A1ATD) and hepatocellular carcinoma(HCC) in patients with end-stage liver disease(ESLD).METHODS:Patients with cirrhosis and ESLD referred to the Cleveland Clinic Foundation for liver transplantation between 2003 and 2014 were included in the study(N = 675). ESLD was defined as having histological features of cirrhosis and/or radiological evidence of cirrhosis in the context of portal hypertension(ascites,variceal bleeding,thrombocytopenia,or hepatic encephalopathy). A1 ATD was diagnosed using phenotype characterization(MZ or ZZ),liver biopsy detection of PAS-positive diastaseresistant(PAS+) globules,or both. Patients with other causes of liver diseases such as hepatitis C virus(HCV),alcoholic liver disease and non-alcoholic steatohepatitis(NASH) or NASH were also included in the study. HCC was diagnosed by using imaging modalities,biopsy findings,or explanted liver inspection. Follow-up time was defined as the number of years from the diagnosis of cirrhosis to the diagnosis of hepatocellular carcinoma,or from the diagnosis of cirrhosis to the last follow up visit. The rate of HCC was assessed using time-tointerval analysis for interval censored data.RESULTS:This study included 675 patients. 7% of subjects had A1ATD(n = 47). Out of all subjects who did not have A1 ATD,46% had HCV,17% had alcoholic liver disease,19% had NASH and 18% had another primary diagnosis. Of the 47 subjects with A1 ATD,15 had a primary diagnosis of A1ATD(PI*ZZ phenotype and PAS+ globules),8 had a PI*MZ phenotype alone,14 had PAS+ alone,and 10 had both the PI*MZ phenotype and PAS+. Median follow-up time was 3.4(25th,75 th percentiles:1,5.2) years. The overall rate of hepatocellular carcinoma in all subjects was 29%(n = 199). In the A1 ATD group,the incidence rate of HCC was 8.5% compared to 31% in the group of patients with other causes of cirrhosis(P = 0.001). Patients with ESLD due to A1 ATD had the lowest yearly cumulative rate of hepatocellular carcinoma at 0.88% per year compared to 2.7% for those with HCV cirrhosis,1.5% in patients with NASH and 0.9% in alcohol-induced liver disease(P < 0.001).CONCLUSION:Within this group of patients with ESLD,there was no significant association between A1 ATD and increased risk of HCC.
引用
下载
收藏
页码:1427 / 1432
页数:6
相关论文
共 50 条
  • [1] Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease
    Antoury, Clara
    Lopez, Rocio
    Zein, Nizar
    Stoller, James K.
    Alkhouri, Naim
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (10) : 1427 - 1432
  • [2] Alpha-1 Antitrypsin Deficiency and the Risk of Hepatocellular Carcinoma in Patients With End-Stage Liver Disease
    Antoury, Clara
    Lopez, Rocio
    Zein, Nizar
    Stoller, James
    Alkhouri, Naim
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S138 - S138
  • [3] Association of heterozygote Alpha-1 Antitrypsin deficiency with development of end-stage liver disease
    Isler, BM
    Aranda-Michel, J
    Weber, FL
    Sherman, KE
    GASTROENTEROLOGY, 2001, 120 (05) : A565 - A565
  • [4] Alpha-1 Antitrypsin Deficiency Liver Disease
    Suri, Anandini
    Patel, Dhiren
    Teckman, Jeffrey H.
    CLINICS IN LIVER DISEASE, 2022, 26 (03) : 391 - 402
  • [5] Alpha-1 antitrypsin deficiency liver disease
    Patel, Dhiren
    McAllister, Shannon L.
    Teckman, Jeffrey H.
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
  • [6] Alpha-1 antitrypsin deficiency and liver disease
    Braillon, Alain
    Nguyen-Khac, Eric
    AMERICAN JOURNAL OF MEDICINE, 2008, 121 (06): : E25 - E25
  • [7] HEPATOCELLULAR CARCINOMA AND PARTIAL DEFICIENCY OF ALPHA-1 ANTITRYPSIN (MZ)
    RAWLINGS, W
    MOSS, J
    COOPER, HS
    HAMILTON, SR
    ANNALS OF INTERNAL MEDICINE, 1974, 81 (06) : 771 - 773
  • [8] LIVER TRANSPLANTATION FOR ALPHA-1 ANTITRYPSIN DEFICIENCY: HEPATOCELLULAR CARCINOMA IS COMMON AND DETERIORATES SURVIVAL
    Kok, K.
    Porte, R. J.
    Adam, R.
    van den Berg, A.
    Scheenstra, R.
    Metselaar, H.
    van Hoek, B.
    van Oijen, M. G.
    Drenth, J. P.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S193 - S194
  • [9] ALPHA-1 ANTITRYPSIN DEFICIENCY AND LIVER DISEASE IN CHILDHOOD
    Cardoso, P.
    Nobre, S.
    Ferreira, S.
    Goncalves, I.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S813 - S814
  • [10] Alpha-1 antitrypsin deficiency and liver disease -: Reply
    Koehnlein, Thomas
    Welte, Tobias
    AMERICAN JOURNAL OF MEDICINE, 2008, 121 (06): : E27 - E27